secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001493152-23-016287
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dare Bioscience Q1 cash $19.8M; Sildenafil Cream Phase 2b data and XACIATO launch expected Q2
--------------------------------------------------------------------------------

- Cash $19.8M at March 31; G&A $3.3M (up from $2.6M) on commercial-readiness and email fraud loss; R&D $5.0M (down from $5.8M).
- Expects Sildenafil Cream Phase 2b topline data in Q2 2023 for FSAD, a condition with no FDA-approved treatments.
- XACIATO first commercial sale by Organon expected Q2 2023, triggering $2.5M milestone payment to Daré.
- Ovaprene pivotal Phase 3 contraceptive study start mid-2023 under NIH/NICHD CRADA; DARE-HRT1 and DARE-VVA1 IND prep ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000149315223016287/0001493152-23-016287-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000149315223016287/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016287

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer